NASDAQ:VTGN - Vistagen Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.79 -0.01 (-1.25 %) (As of 05/27/2019 06:00 AM ET)Previous Close$0.7898Today's Range$0.72 - $0.8152-Week Range$0.52 - $2.44Volume396,490 shsAverage Volume338,102 shsMarket Capitalization$33.66 millionP/E RatioN/ADividend YieldN/ABeta-0.42 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of drug rescue NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California. Receive VTGN News and Ratings via Email Sign-up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTGN Previous Symbol CUSIPN/A CIK1411685 Webhttp://www.vistagen.com/ Phone650-577-3600Debt Debt-to-Equity RatioN/A Current Ratio3.64 Quick Ratio3.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.25 million Price / Sales26.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.30 per share Price / Book2.63Profitability EPS (Most Recent Fiscal Year)($1.11) Net Income$-14,340,000.00 Net MarginsN/A Return on Equity-581.50% Return on Assets-255.52%Miscellaneous Employees9 Outstanding Shares42,620,000Market Cap$33.66 million Next Earnings Date6/25/2019 (Estimated) OptionableNot Optionable Vistagen Therapeutics (NASDAQ:VTGN) Frequently Asked Questions What is Vistagen Therapeutics' stock symbol? Vistagen Therapeutics trades on the NASDAQ under the ticker symbol "VTGN." How were Vistagen Therapeutics' earnings last quarter? Vistagen Therapeutics Inc (NASDAQ:VTGN) announced its quarterly earnings data on Tuesday, February, 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.03. View Vistagen Therapeutics' Earnings History. When is Vistagen Therapeutics' next earnings date? Vistagen Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, June 25th 2019. View Earnings Estimates for Vistagen Therapeutics. What price target have analysts set for VTGN? 3 equities research analysts have issued 12-month price targets for Vistagen Therapeutics' stock. Their predictions range from $6.00 to $22.00. On average, they anticipate Vistagen Therapeutics' stock price to reach $11.3333 in the next year. This suggests a possible upside of 1,335.0% from the stock's current price. View Analyst Price Targets for Vistagen Therapeutics. What is the consensus analysts' recommendation for Vistagen Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vistagen Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vistagen Therapeutics. What are Wall Street analysts saying about Vistagen Therapeutics stock? Here are some recent quotes from research analysts about Vistagen Therapeutics stock: 1. According to Zacks Investment Research, "VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. " (5/11/2019) 2. Maxim Group analysts commented, "VistaGen announced that it has expanded its partnership with Pherin Pharmaceuticals (private) and acquired rights for PH10, a pherin steroid in a nasal spray formulation. Recall that 3-ready pherin steroid for social anxiety disorder, was acquired from Pherin Pharmaceuticals last month." (10/25/2018) 3. Chardan Capital analysts commented, "We understand that trial centers are continuing to come online and patient enrollment is on track. Of note, also, is the anticipated data in 2H18 from the NIMH-sponsored 25-patient phase II trial (NCT02484456) of AV-101 as a monotherapy, which will likely provide helpful insight on biomarker and mechanistic data. To support the continued development of AV-101, VistaGen has been issued a patent on the therapeutic uses of AV-101 in MDD (similar to methods of use) as well as a patent on unit dose formulations (almost tantamount to composition of matter). The patents provide protection for AV-101 through 2034." (6/29/2018) Has Vistagen Therapeutics been receiving favorable news coverage? News headlines about VTGN stock have trended very positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vistagen Therapeutics earned a news impact score of 3.1 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Vistagen Therapeutics' key competitors? Some companies that are related to Vistagen Therapeutics include CytoDyn (CYDY), Humanigen (HGEN), Fortress Biotech (FBIO), Chembio Diagnostics (CEMI), Corvus Pharmaceuticals (CRVS), Ocular Therapeutix (OCUL), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Aptinyx (APTX), Tocagen (TOCA), AgeX Therapeutics (AGE), Arbutus Biopharma (ABUS), Bellicum Pharmaceuticals (BLCM), Spring Bank Pharmaceuticals (SBPH) and Imprimis Pharmaceuticals (IMMY). What other stocks do shareholders of Vistagen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Advaxis (ADXS), Rite Aid (RAD), Lithium Americas (LAC), Matinas BioPharma (MTNB), Yamana Gold (AUY), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and Crispr Therapeutics (CRSP). Who are Vistagen Therapeutics' key executives? Vistagen Therapeutics' management team includes the folowing people: Mr. Shawn K. Singh, CEO & Director (Age 56)Dr. H. Ralph Snodgrass, Founder, Pres, Chief Scientific Officer & Director (Age 69)Mr. Jerrold D. Dotson, CFO, VP & Sec. (Age 66)Mr. Mark Adrian McPartland, VP of Corp. Devel. (Age 53)Dr. Mark A. Smith, Chief Medical Officer (Age 64) Who are Vistagen Therapeutics' major shareholders? Vistagen Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Ladenburg Thalmann Financial Services Inc. (0.41%) and Jane Street Group LLC (0.05%). View Institutional Ownership Trends for Vistagen Therapeutics. Which major investors are buying Vistagen Therapeutics stock? VTGN stock was purchased by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc. and Jane Street Group LLC. View Insider Buying and Selling for Vistagen Therapeutics. How do I buy shares of Vistagen Therapeutics? Shares of VTGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Vistagen Therapeutics' stock price today? One share of VTGN stock can currently be purchased for approximately $0.7898. How big of a company is Vistagen Therapeutics? Vistagen Therapeutics has a market capitalization of $33.66 million and generates $1.25 million in revenue each year. The company earns $-14,340,000.00 in net income (profit) each year or ($1.11) on an earnings per share basis. Vistagen Therapeutics employs 9 workers across the globe. What is Vistagen Therapeutics' official website? The official website for Vistagen Therapeutics is http://www.vistagen.com/. How can I contact Vistagen Therapeutics? Vistagen Therapeutics' mailing address is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-577-3600 or via email at [email protected] MarketBeat Community Rating for Vistagen Therapeutics (NASDAQ VTGN)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 194 (Vote Outperform)Underperform Votes: 124 (Vote Underperform)Total Votes: 318MarketBeat's community ratings are surveys of what our community members think about Vistagen Therapeutics and other stocks. Vote "Outperform" if you believe VTGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/27/2019 by MarketBeat.com StaffFeatured Article: How to find the components of the quick ratio Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.